Skip to main content
. 2017 Aug 9;34(8):2043–2057. doi: 10.1007/s12325-017-0589-5

Fig. 2.

Fig. 2

a Proportion of NOACs use within the overall use of OAC before the enrollment visit/hospitalization (light blue) and after the enrolling visit/at discharge (dark blue). b Use of NOACs across the stroke (CHA2DS2-VASc and CHADS2) and bleeding (HAS-BLED) risk strata. NOAC non-vitamin K oral anticoagulant